Y-mabs to present at 2024 asco annual meeting

New york, april 25, 2024 (globe newswire) -- y-mabs therapeutics, inc. (the “company” or “y-mabs”) (nasdaq: ymab), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody-based therapeutic products for the treatment of cancer, today announced the acceptance of four abstracts at the 2024 american society of clinical oncology (“asco”) annual meeting, taking place may 31 – june 4, 2024 in chicago, il.
YMAB Ratings Summary
YMAB Quant Ranking